According to GuruFocus Insider Data, the recent chief financial officer buys were Forterra Inc. (FRTA, Financial), HC2 Holdings Inc. (HCHC, Financial) and Assertio Therapeutics Inc. (ASRT, Financial).
Forterra CFO bought 36,745 shares
Executive Vice President and CFO Charles Rodney Brown bought 36,745 shares for $4.16 per share on March 15. Since then, the share price has declined 1.92%.
Forterra has a market cap of $261.940 million; its shares were traded around $4.08. The company has a price-sales ratio of 0.18.
Forterra announced its third-quarter results with revenue of $434.51 million and gross profit of $77.14 million, while the net income was $5.50 million. 2017 total revenue was $1.58 billion, a 16% increase from 2016. The gross profit was $255.51 million, a 9% decrease. The net loss was $2.06 million.
CEO Jeff Bradley bought 40,000 shares for $3.8 per share on March 15. Since then, the stock has gained 7.37%. Executive Vice President and General Counsel Lori M. Browne bought 6,118 shares for $4.38 per share on March 14. Since then, the price has fallen 6.85%.
HC2 Holdings CFO bought 9,600 shares
CFO Michael J. Sena bought 9,600 shares for $2.61 per share on March 15. Since then, the share price has fallen 1.92%. HC2 Holdings has a market cap of $115.130 million; its shares were traded around $2.56. The company has a price-earnings ratio of 0.93 and a price-sales ratio of 0.06.
HC2 Holdings announced fourth-quarter results with revenue of $524.88 million and gross profit of $55.70 million, while the net loss was $11.84 million. 2017 total revenue was $1.63 billion, a 5% increase from 2016. The gross profit was $212.3 million, a 17% increase from the year prior. The net loss was $46.90 million.
Chairman, President and CEO Philip Falcone bought 20,000 shares for $2.67 per share on March 15. Since then, the stock has tumbled 4.12%.
Assertio Therapeutics CFO bought 6,000 shares
Senior Vice President and CFO Daniel A. Peisert bought 6,000 shares for $4.18 per share on March 14. The share price has risen 21.29% since then. Assertio Therapeutics has a market cap of $325.810 million; its shares were traded around $5.07. The company has a price-earnings ratio of 12.08 and a price-sales ratio of 1.21. Over the past five years, the company had an annual average earnings growth of 33.80%.
Assertio Therapeutics announced its fourth-quarter results with revenue of $42.60 million and gross profit of $41.90 million, while the net loss was $24.14 million. 2018 total revenue was $311.77 million, a 18% decrease from 2017. The gross profit was $293.29 million, a 5% decrease from the year prior. The net income was $36.91 million.
Director, President and CEO Arthur J. Higgins bought 10,000 shares for $4.17 per share on March 14. Since then, the stock has climbed 21.58%.Â
Disclosure: None.
